PMID- 24345322
OWN - NLM
STAT- MEDLINE
DCOM- 20140424
LR  - 20151119
IS  - 1879-1891 (Electronic)
IS  - 0002-9394 (Linking)
VI  - 157
IP  - 3
DP  - 2014 Mar
TI  - Choroidal neovascularization associated with focal choroidal excavation.
PG  - 710-8.e1
LID - S0002-9394(13)00781-2 [pii]
LID - 10.1016/j.ajo.2013.12.011 [doi]
AB  - PURPOSE: To describe the clinical and imaging characteristics of choroidal 
      neovascularization (CNV) accompanied by focal choroidal excavation. DESIGN: 
      Retrospective, interventional case series. METHODS: The medical records of 16 
      patients (16 eyes) were reviewed. Imaging findings including fluorescein 
      angiography (FA), indocyanine green angiography, and spectral-domain optical 
      coherence tomography (SD OCT) were analyzed. RESULTS: CNV complexes were 
      primarily located beneath the retinal pigment epithelium (type 1 CNV) in 9 eyes 
      and in the subneurosensory retinal space (type 2 CNV) in 7 eyes, as assessed by 
      SD OCT. Seven of 8 patients over 50 years old had type 1 CNV, and 6 of 8 patients 
      under 50 had type 2 lesions. All 7 eyes with type 2 CNV exhibited classic CNV on 
      FA. Additionally, 7 of 9 eyes with type 1 CNV had the classic pattern, and in 
      these eyes, the CNV complexes were confined to the concavity of choroidal 
      excavation. In 15 patients treated by anti-vascular endothelial growth factor 
      (anti-VEGF) injections, the mean best-corrected visual acuity improved from 20/44 
      to 20/26 with a mean of 3.7 injections during a mean follow-up period of 14.5 
      months. CONCLUSIONS: The CNV growth pattern and extent seem to be determined by 
      the degree of damage to the retinal pigment epithelium/Bruch membrane complex 
      resulting from choroidal excavation, as well as age. Neovascular complexes tend 
      to be located within the boundary of choroidal excavation and are revealed as 
      classic patterns on FA, even in type 1 CNV. Anti-VEGF was notably effective for 
      treating these lesions, with a low rate of recurrence.
CI  - Copyright (c) 2014 Elsevier Inc. All rights reserved.
FAU - Lee, Jae Hyung
AU  - Lee JH
AD  - Department of Ophthalmology, Seoul St. Mary's Hospital, College of Medicine, The 
      Catholic University of Korea, Seoul, South Korea.
FAU - Lee, Won Ki
AU  - Lee WK
AD  - Department of Ophthalmology, Seoul St. Mary's Hospital, College of Medicine, The 
      Catholic University of Korea, Seoul, South Korea. Electronic address: 
      wklee@catholic.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20131215
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Coloring Agents)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - IX6J1063HV (Indocyanine Green)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Bevacizumab
MH  - Choroid/*pathology
MH  - Choroidal Neovascularization/*diagnosis/drug therapy
MH  - Coloring Agents
MH  - Female
MH  - Fluorescein Angiography
MH  - Humans
MH  - Indocyanine Green
MH  - Male
MH  - Middle Aged
MH  - Ranibizumab
MH  - Retinal Pigment Epithelium/pathology
MH  - Retrospective Studies
MH  - Tomography, Optical Coherence
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
MH  - Visual Acuity/physiology
EDAT- 2013/12/19 06:00
MHDA- 2014/04/25 06:00
CRDT- 2013/12/19 06:00
PHST- 2013/08/10 00:00 [received]
PHST- 2013/12/03 00:00 [revised]
PHST- 2013/12/04 00:00 [accepted]
PHST- 2013/12/19 06:00 [entrez]
PHST- 2013/12/19 06:00 [pubmed]
PHST- 2014/04/25 06:00 [medline]
AID - S0002-9394(13)00781-2 [pii]
AID - 10.1016/j.ajo.2013.12.011 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 2014 Mar;157(3):710-8.e1. doi: 10.1016/j.ajo.2013.12.011. Epub 
      2013 Dec 15.